Report of Foreign Issuer (6-k)
March 08 2017 - 6:05AM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
6-K
Report
of Foreign Private Issuer
Pursuant to Rule 13
A
-16
or 15
d
-16 of
The
Securities Exchange Act of 1934
For
the month of
March 2017
C
OMMISSION
F
ILE
N
umber
.
000-29338
CARDIOME
PHARMA CORP.
(Translation
of registrant’s name into English)
1441
Creekside Drive, 6th floor
Vancouver,
British Columbia, V6J 4S7, CANADA
(Address
of principal executive offices)
Indicate
by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F
Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐
DOCUMENTS INCLUDED AS PART OF THIS REPORT
Exhibit
|
|
Description
|
|
|
|
99.1
|
|
Management’s Discussion and Analysis of Financial Condition and Results of Operations
|
99.2
|
|
Cardiome Pharma Corp. Consolidated Financial Statements for the years ended December 31, 2016 and 2015
|
|
|
|
Exhibits 99.1 and 99.2 of this report on Form 6-K are incorporated by reference into the Company’s registration statement
on Form F-10 (File No. 333-193645) and registration statements on Form S-8 (File No. 333-199091 and File No. 333-199092).
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorized.
|
CARDIOME
PHARMA CORP.
|
|
(Registrant)
|
|
|
|
Date: March 7, 2017
|
By:
|
/s/ Jennifer Archibald
|
|
|
Name: Jennifer Archibald
|
|
|
Title: Chief Financial Officer
|
Correvio Pharma (NASDAQ:CORV)
Historical Stock Chart
From Apr 2024 to May 2024
Correvio Pharma (NASDAQ:CORV)
Historical Stock Chart
From May 2023 to May 2024